- Home
- MPLX vs ZTS Comparison
MPLX vs ZTS Comparison
Compare MPLX & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MPLX | ZTS |
|---|---|---|
| Founded | 2012 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.8B | 48.7B |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | MPLX | ZTS |
|---|---|---|
| Price | $56.51 | $118.57 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 11 |
| Target Price | $61.44 | ★ $156.20 |
| AVG Volume (30 Days) | 1.5M | ★ 3.0M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 7.64% | 1.77% |
| EPS Growth | N/A | ★ 10.05 |
| EPS | N/A | ★ 6.02 |
| Revenue | N/A | ★ $9,467,000,000.00 |
| Revenue This Year | $12.50 | $5.68 |
| Revenue Next Year | $4.72 | $4.86 |
| P/E Ratio | ★ $11.76 | $19.92 |
| Revenue Growth | N/A | ★ 2.28 |
| 52 Week Low | $47.94 | $113.30 |
| 52 Week High | $59.98 | $172.23 |
Technical Indicators
Market Signals| Indicator | MPLX | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 43.60 | 48.73 |
| Support Level | $53.68 | $115.35 |
| Resistance Level | $56.73 | $129.28 |
| Average True Range (ATR) | 1.17 | 2.76 |
| MACD | -0.23 | 0.66 |
| Stochastic Oscillator | 39.00 | 71.81 |
Price Performance
Historical ComparisonAbout MPLX MPLX LP
MPLX is a partnership that owns pipelines and gathering and processing assets with extensive holdings in the Appalachian and Permian regions. The asset base is made up of crude oil and refined products assets dropped down from Marathon Petroleum, its sponsor, and natural gas and natural gas liquids gathering and processing assets that were purchased or built.
About ZTS Zoetis Inc.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its USA business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.